Naslov
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis: a multicenter, prospective, cohort study

Autori
Kardenas-Jaen, Karina ; Archibugi, Livia ; Poropat, Goran ; Korpela, Taija ; Maisonneuve ; Aparicio, Jose R ; Udd, Marianne ; Štimac, Davor ; Arcidiacono, Paolo G ; De Pretis, Niccolo ; Valente, Roberto ; Di Giulio, Emilio ; Casellas, Juan A ; Kylanpaa, Leena ; Hauser, Goran ; Mariani, Alberto ; Gabbrielli, Armando ; Lohr, Matthias ; Vanella, Giuseppe ; Rainio, Mia ; Brozzi, Lorenzo ; Arnelo, Urban ; Fagerstrom, Niklas ; Capurso, Gabriele ; De-Madaria, Enrique

Izvornik
Digestive Endoscopy (0915-5635) 1 (2020), 1; 1-1

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
endoscopic retrograde cholangiopancreatography ; hydroxymethylglutaryl-CoA reductase inhibitors ; pancreatitis ; prevention ; salicylates

Sažetak
Objectives: post-endoscopic retrograde cholangiopancreatography (ERCP) acute pancreatitis (PEP) is a frequent complication of this endoscopic procedure. Chronic statin intake has been linked to lower incidence and severity of acute pancreatitis (AP). Periprocedural rectal administration of non-steroidal anti- inflammatory drugs is protective against PEP, but the role of chronic acetylsalicylic-acid (ASA) treatment is unclear. We aimed to investigate whether statins and chronic ASA intake are associated with lower risk of PEP. Methods: an international, multicenter, prospective cohort study. Consecutive patients undergoing ERCP in seven european centers were included. Patients were followed-up to detect those with PEP. Multivariate analysis by means of binary logistic regression was performed, and adjusted odds ratios (aORs) were calculated. Results: a total of 1, 150 patients were included, and 70 (6.1%) patients developed PEP. Among statins users, 8.1% developed PEP vs. 5.4% among non-users (p = 0.09). Multivariate analysis showed no association between statin use and PEP incidence (aOR 1.68 (95% CI 0.94- 2.99, p = 0.08). Statin use had no effect on severity of PEP, being mild in 92.0% of statin users vs. 82.2% in non-statin users (p = 0.31). Chronic ASA use was not associated with PEP either (aOR 1.02 (95% CI 0.49-2.13), p = 0.96). Abuse of alcohol and previous endoscopic biliary sphincterotomy were protective factors against PEP, while >1 pancreatic guidewire passage, normal bilirubin values, and duration of the procedure >20 minutes, were risk factors. Conclusions: the use of statins or ASA is not associated with a lower risk or a milder course of PEP.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Ahead of print

POVEZANOST RADA